Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 USD | -5.08% | -10.40% | +103.64% |
04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
04-01 | Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+103.64% | 43.55M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- XLO Stock
- News Xilio Therapeutics, Inc.
- Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating